Skip to content
2000
Volume 10, Issue 8
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Recent progress in enzyme engineering has led to versions of human butyrylcholinesterase (BChE) that hydrolyze cocaine efficiently in plasma, reduce concentrations reaching reward neurocircuity in the brain, and weaken behavioral responses to this drug. Along with enzyme advances, increasingly avid anti-cocaine antibodies and potent anti-cocaine vaccines have also been developed. Here we review these developments and consider the potential advantages along with the risks of delivering drug-intercepting proteins via gene transfer approaches to treat cocaine addiction.

Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/187152711799219398
2011-12-01
2025-09-21
Loading full text...

Full text loading...

/content/journals/cnsnddt/10.2174/187152711799219398
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test